Work

Supplementary Figures 1 - 3 from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 806K, Supplemental Figure 1. MRI scans at the indicated time points showing tumor burden in EML4-ALK lung cancer mice treated by crizotinib. Multiple scans from a total of 4 mice are shown. Supplemental Figure 2. Representative MRI images showing that EML4-ALK F1174L mutant lung cancers respond to 17-DMAG and TAE684. Note the development of acquired resistance to 17-DMAG and TAE684 after prolonged treatment. Supplemental Figure 3. Acquired resistance to 17-DMAG and TAE684 in mice bearing tumors driven by the EML4-ALK F1174L mutant can be overcome by the combination of the two drugs.

DOI: 10.1158/1078-0432.22449362

Authors: Zhao Chen, Esra Akbay, Oliver Mikse, Tanya Tupper, Katherine Cheng, Yuchuan Wang, Xiaohong Tan, Abigail Altabef, Sue-Ann Woo, Liang Chen, Jacob B. Reibel, Pasi A. Janne, Norman E. Sharpless, Jeffrey A. Engelman, Geoffrey I. Shapiro, Andrew L. Kung, Kwok-Kin Wong

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361818800

Cites:

Cited by:

Related to: 10